Ilaris 150 (Canakinumab Vials) 150mg/ml x 6ml

Canakinumab is a selective human monoclonal antibody that binds to interleukin-1 beta (IL-1β), neutralizing its activity. By inhibiting IL-1β, it reduces inflammation and the associated symptoms in various auto-inflammatory and autoimmune conditions. This mechanism helps manage symptoms and improve the quality of life for patients with these conditions.

The usual dose of Ilaris 150 is determined by a healthcare provider based on the patient's condition, age, and weight. It is typically administered as an injection, and the dosage and frequency are tailored to the specific needs of the patient. Always follow the prescribing healthcare provider's instructions for the correct dosage and administration.

The safety of Ilaris 150 during pregnancy and breastfeeding has not been established. Patients who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Ilaris 150. The healthcare provider can provide guidance based on the patient's specific situation and medical history.

To order Ilaris 150 from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask the buyer to confirm their trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

Ilaris 150 is a monoclonal antibody that specifically targets interleukin-1 beta (IL-1β), making it effective for conditions driven by excessive IL-1β activity. Compared to other treatments, such as corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs), Ilaris 150 offers a more targeted approach with potentially fewer systemic side effects. However, the choice of treatment depends on the patient's specific condition and response to therapy.

Ilaris 150 should be stored at 2-8°C, kept refrigerated, and protected from light. It should not be frozen or shaken. The medication should be kept in its original packaging until use. Always follow the storage instructions provided by the manufacturer to ensure the stability and effectiveness of the medication.

Ilaris 150 is administered as an injection, typically by a healthcare provider. The injection is usually given subcutaneously (under the skin) or intravenously (into a vein), depending on the specific instructions provided by the healthcare provider. Patients should follow the administration instructions carefully to ensure proper use of the medication.

The most serious risks associated with Ilaris 150 include serious infections, such as tuberculosis and opportunistic infections, allergic reactions, including anaphylaxis, and macrophage activation syndrome (MAS). Patients should be monitored closely for signs of these complications, and any concerning symptoms should be reported to a healthcare provider immediately.

Ilaris 150 should not be used by patients with a known hypersensitivity to canakinumab or any of the excipients in the formulation. Patients with active infections or those who have recently received live vaccines should also avoid using Ilaris 150. Always consult a healthcare provider to determine if Ilaris 150 is appropriate for your specific medical situation.